rmulation
of tramadol, is being commercially launched in key markets globally. The
Company also has a robust pipeline of follow-on products in both
pre-clinical and clinical development. Labopharm's vision is to become a
fully integrated, international, specialty pharmaceutical company with the
capability to internally develop and commercialize its own products. For
more information, please visit
http://www.labopharm.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein and depend on a number
of factors, including the uncertainties related to the regulatory process
for drug approval and the commercialization of the Company's products, if
they are approved. Investors should consult the Company's ongoing quarterly
filings and annual reports for additional information on risks and
uncertainties relating to these forward-looking statements. The reader is
cautioned not to rely on these forward-looking statements. The Company
disclaims any obligation to update these forward-looking statements.
'/>"/>SOURCE Labopharm Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy2.
Labopharm provides update on U.S. regulatory process for once-daily Tramadol3.
Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug4.
Labopharm appeals FDAs decision on once-daily tramadol5.
Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)6.
Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference7.
Labopharm Reports Results for Third Quarter Fiscal 20078.
Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store9.
DaVita Receives Civil Complaint10.
Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis11.
Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility